For research use only. Not for therapeutic Use.
Brivanib Alaninate（Cat No.:I004451）is an oral prodrug of brivanib, a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) signaling pathways. By targeting these pathways, brivanib alaninate disrupts tumor angiogenesis and cell proliferation, making it a potential therapeutic option for treating various cancers, including hepatocellular carcinoma and colorectal cancer. Its dual inhibition mechanism offers enhanced efficacy by blocking blood vessel formation and tumor growth. Brivanib alaninate has been evaluated in clinical trials for its ability to improve outcomes in patients with advanced-stage cancers.
| Catalog Number | I004451 |
| CAS Number | 649735-63-7 |
| Synonyms | [(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-yl] (2S)-2-aminopropanoate |
| Molecular Formula | C₂₂H₂₄FN₅O₄ |
| Purity | ≥95% |
| Target | VEGFR |
| Solubility | ≥22.05 mg/mL in DMSO; insoluble in H2O; ≥10.03 mg/mL in EtOH |
| Storage | Store at -20°C |
| IC50 | 25 nM |
| IUPAC Name | [(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-yl] (2S)-2-aminopropanoate |
| InChI | InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1 |
| InChIKey | LTEJRLHKIYCEOX-OCCSQVGLSA-N |
| SMILES | CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@H](C)N)C |
| Reference | </br>1:Application of In-line Focused Beam Reflectance Measurement to Brivanib Alaninate Wet Granulation Process to Enable Scale-up and Attribute-based Monitoring and Control Strategies. Narang AS, Stevens T, Macias K, Paruchuri S, Gao Z, Badawy S.J Pharm Sci. 2017 Jan;106(1):224-233. doi: 10.1016/j.xphs.2016.08.025. Epub 2016 Oct 19. PMID: 27771049 </br>2:Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets. Badawy SI, Narang AS, LaMarche KR, Subramanian GA, Varia SA, Lin J, Stevens T, Shah PA.J Pharm Sci. 2016 Jan;105(1):168-81. doi: 10.1016/j.xphs.2015.11.023. Epub 2016 Jan 13. PMID: 26852852 </br>3:Real-time assessment of granule densification in high shear wet granulation and application to scale-up of a placebo and a brivanib alaninate formulation. Narang AS, Sheverev VA, Stepaniuk V, Badawy S, Stevens T, Macias K, Wolf A, Pandey P, Bindra D, Varia S.J Pharm Sci. 2015 Mar;104(3):1019-34. doi: 10.1002/jps.24233. Epub 2014 Dec 2. PMID: 25470221 </br>4:Quality by design development of brivanib alaninate tablets: degradant and moisture control strategy. Badawy SI, Lin J, Gokhale M, Desai S, Nesarikar VV, LaMarche KR, Subramanian GA, Narang AS.Int J Pharm. 2014 Jul 20;469(1):111-20. doi: 10.1016/j.ijpharm.2014.04.059. Epub 2014 Apr 26. PMID: 24780101 </br>5:Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. Lin HC, Huang YT, Yang YY, Lee PC, Hwang LH, Lee WP, Kuo YJ, Lee KC, Hsieh YC, Liu RS.J Gastroenterol Hepatol. 2014 May;29(5):1073-82. doi: 10.1111/jgh.12480. PMID: 24325631 </br>6:Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O/’Callaghan CJ.J Clin Oncol. 2013 Jul 1;31(19):2477-84. doi: 10.1200/JCO.2012.46.0543. Epub 2013 May 20. PMID: 23690424 </br>7:Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DS.Br J Cancer. 2011 Jun 28;105(1):44-52. doi: 10.1038/bjc.2011.182. Epub 2011 May 31. PMID: 21629245 Free PMC Article</br>8:Brivanib alaninate for cancer. Diaz-Padilla I, Siu LL.Expert Opin Investig Drugs. 2011 Apr;20(4):577-86. doi: 10.1517/13543784.2011.565329. Epub 2011 Mar 11. Review. PMID: 21391890 </br>9:Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans. Gong J, Gan J, Caceres-Cortes J, Christopher LJ, Arora V, Masson E, Williams D, Pursley J, Allentoff A, Lago M, Tran SB, Iyer RA.Drug Metab Dispos. 2011 May;39(5):891-903. doi: 10.1124/dmd.110.037341. Epub 2011 Feb 2. PMID: 21289073 Free Article</br>10:Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, Li T, Ross EA, Oseni S, Fargnoli J, Jordan VC.Eur J Cancer. 2010 Jun;46(9):1537-53. doi: 10.1016/j.ejca.2010.02.018. Epub 2010 Mar 18. PMID: 20303261 Free PMC Article |
